by Peter Ciszewski | May 31, 2018
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses the Development Award from the Cystic Fibrosis Foundation. The Development Award enables Corbus to execute its Phase 2b study of its novel, oral, pro-resolving drug lenabasum in approximately 415 people...
by Peter Ciszewski | May 30, 2018
New York, NY and Jackson, NJ – (May 30, 2018) – Today, CheckRare, an innovative learning platform for rare diseases, and the American Academy of CME, Inc., a 501(c)(3) education foundation focused on empowering and inspiring the healthcare team and its members to...
by Peter Ciszewski | May 30, 2018
Annette Bakker, PhD, President and Chief Scientific Officer, of the Children’s Tumor Foundation discusses how her company works with the pharma and biotech industries, specifically SpringWorks Therapeutics. SpringWorks Therapeutics is planning to initiate...
by Peter Ciszewski | May 29, 2018
Luca Santarelli, MD of Therachon discusses reaching out to achondroplasia advocacy groups. Achondroplasia is an autosomal dominant disorder characterized by dwarfism and disproportionate shortness of limbs, accompanied by life-altering complications....
by Peter Ciszewski | May 28, 2018
The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in...
